Physician profile
Paul E Larose
NPI 1245210046
$20,747.49
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $6,195 · 2021: $1,519.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedplasma LLC | $20,170.00 | 2019-2021 | |
| Abbvie INC. | $224.17 | 2019-2021 | |
| Therapeuticsmd, INC. | $86.12 | 2019 | |
| Roche Diagnostics Corporation | $44.83 | 2019 | |
| Astellas Pharma US INC | $38.68 | 2020 | |
| Exeltis, USA INC. | $37.76 | 2019-2020 | |
| Amgen INC. | $26.59 | 2019 | |
| Daiichi Sankyo INC. | $24.83 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.53 | 2019-2020 | |
| Aspira Women'S Health INC | $16.48 | 2020 | |
| Duchesnay USA Incorporated | $14.57 | 2019 | |
| Allergan, INC. | $14.20 | 2020 | |
| Hologic Sales and Service, LLC | $12.65 | 2020 | |
| Coopersurgical, INC. | $12.08 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Larose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.